GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Apr 3, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Apr 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on April 2, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing is a report of a foreign private issuer for the month of April 2025.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not contain significant new financial or strategic information.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker
- April 2, 2025 (date) — Date of purchase
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, specifically reporting a transaction in its own shares.
Who is acting as GSK's corporate stockbroker for this transaction?
Citigroup Global Markets Limited is acting as GSK's corporate stockbroker.
On what date did GSK purchase its shares?
GSK purchased its ordinary shares on April 2, 2025.
What type of shares did GSK purchase?
GSK purchased its ordinary shares of 31¼ pence each.
Does GSK file annual reports under Form 20-F or Form 40-F?
GSK indicates that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 3, 2025 regarding GSK plc (GLAXF).